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In this issue of Chemistry & Biology, Lang et al. (2008) add an important step toward a molecular understand-
ing of ribosomal peptide-bond formation: they unravel the involvement of an essential partner of the reaction,
namely the 20-OH group of the 23S rRNA nucleotide A2451.The advent of crystal structures of the ri-
bosomal subunits and somewhat later of
the whole ribosome has revolutionized
our understanding of the ribosome (for
review see Steitz, 2008). Indeed, these
studies led to the phrase ‘‘Ribosome is
a Ribozyme’’ (Cech, 2000), resulting
from the fact that rRNA is the major con-
stituent element for two fundamental pro-
cesses: (1) decoding the mRNA informa-
tion at the A-site decoding center on the
small ribosomal subunit; and (2) peptide-
bond formation at the peptidyltransferase
center on the large ribosomal subunit. Al-
though the structural principles of decod-
ing have been resolved, the evaluation of
the mechanism of peptide-bond forma-
tion is still ongoing.
A peptidyl-tRNA at the P site and an
aminoacyl-tRNA at the A site define the
first step in polypeptide chain elongation
reaction, with both acyl residues attached
to the A76 30 position of their respective
tRNA via an ester bond (Figure 1A, left
panel). The second step is initiated by
a nucleophilic attack by the a-amino
group from the A-tRNA on the carbonyl
carbon of the P-tRNA, resulting in a pep-
tide bond between the peptidyl residue
and the aminoacyl group at the A site
(Figure 1A). TheA site nowcontains a pep-
tidyl-tRNA one aminoacyl residue longer,
whereas a deacylated tRNA resides at
the P site. An early model, based on
chemical rates measured for related
chemical reactions, suggested that the
enzymatic rate acceleration is mainly
achieved by the precise stereochemical
alignment of the substrates, the 30-termi-
nal CCA ends of both tRNAs with their re-
spective residues (physical concept: tem-
plate model). Additionally, evidence for an
involvement of a general acid-base catal-
ysis was also presented (chemical con-
cept: a transient formation of a covalent
bond between enzyme and substrate;Nierhaus et al., 1980). Indeed, the first
crystal structure of the large ribosomal
subunit containing a transition state ana-
log at the peptidyltransferase center (Nis-
sen et al., 2000) confirmed biochemical
evidence (Green et al., 1998) and showed
that the CCA-ends of both A- and P-tRNA
are specifically recognized and firmly held
in place by a number of specific contacts
between rRNA and tRNAs nucleotides.
Furthermore, the structure suggested
that the N3 of A2451 is part of general
acid-base catalysis mechanism, since it
is within the hydrogen-bond distance to
the a-amino group (see the neighborhood
of N3 and the a-amino groups in
Figure 1B, right panel). This suggestion
led to number of mutational studies, cul-
minating in a mutational study of all nucle-
otide residues at the peptidyltransferase
center, i.e., A2451, U2506, U2585, and
A2602 (Youngman et al., 2004, and refer-
ences therein). The surprising result was
that all bases, including A2451, are not
of primary importance for peptide-bond
formation, but rather for the release of
the peptidyl residue during termination
of protein synthesis. These results simpli-
fied our picture of the elements participat-
ing in peptide-bond formation signifi-
cantly. Thus, an inner nucleotide shell of
the peptidyltransferase center, compris-
ing these four residues important for pep-
tide release, and an outer shell, compris-
ing the A and P loops involved in fixation
of the CCA ends of A- and P-tRNA, were
defined. Eventually, a participation of
a general acid-base catalysis in peptide-
bond formation was questioned and ex-
cluded (Sievers et al., 2004).
These conclusiones per exclusionem
did not address all the players directly in-
volved in peptide bond formation. Two
important observations paved the way
for a deeper understanding of this enzy-
matic activity: (1) the 30-terminal 20-OHChemistry & Biology 15, May 200group of the P-tRNA was shown to play
an essential role for the mechanism of
peptide-bond formation (Dorner et al.,
2003; Weinger et al., 2004), and (2) a sec-
ond 20-OH group was identified to be cru-
cial for peptide bond formation, namely
that of A2451. Interestingly, removal of
the entire nucleobase of A2451 nucleo-
tide, leaving the sugar-phosphate back-
bone intact, does not significantly impair
the rate of peptide-bond formation. In
contrast, removal of the 20-OH of A2451
completely abolishes activity (Figure 1B;
Erlacher et al., 2005). A molecular dynam-
ics study placed the two essential 20-OH
groups into amechanistic context and es-
tablished the important concept of a ‘‘pro-
ton shuttle’’: when the 30-ester bond of the
peptidyl-tRNA at the P site is cleaved,
a proton is delivered from the adjacent
20-OH group, which in turn receives a pro-
ton from the a-amino group of the amino-
acyl-tRNA at the A site (Figure 1B, left
panel; Trobro and A˚qvist, 2005).
What remained to be clarified was the
question of cooperation between the
two essential 20-OH groups during pep-
tide-bond formation (Figure 1B, right
panel). This question is now addressed
by Lang et al. (2008) in this issue of
Chemistry & Biology. In particular they
investigate whether the proton donor or
acceptor capacity of the 20-O of A2451
are essential for formation of a hydrogen
bridge. They report results of chemically
and biochemically challenging experi-
ments, in which they replace the 20-OH
group by –F (no proton donor, retained
proton acceptor capacity), by -H and
-OCH3 (neither proton donor nor acceptor
capacity) and -NH2 (with both proton do-
nor and acceptor capacity). Next, they
test kinetics of peptide-bond formation
in each case. The results are unequivocal:
the proton donor capacity of this group is
essential, but proton acceptor capacity is8 ª2008 Elsevier Ltd All rights reserved 417
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present a convincing model (Figure 1C),
where the 20-OH group of A2451 forms
an H-bond with the 20-OH group of A76
of the P-tRNA during the entire reaction
process. This hydrogen bond bridge has
two important consequences:
(1) A possible fast intramolecular
transesterification of the peptidyl
residue between the 20 and 30 oxy-
gen of A76 of the P-tRNA is
prevented, which is important
since transesterification has been
observed to occur in solution with
rates in the range of the average
rate of an amino-acid incorporation
into the nascent peptide chain and
might therefore interfere with pep-
tidyl transfer reaction unless effec-
tively prevented.
(2) The ribose of the A76 residue of the
P-tRNA is kept in its RNA-unfavor-
able C20-endo configuration (i.e.,
the C20 atom is above the sugar
plane and the C30 below), which is
important for the proton shuttle).
With these new results we reach a satis-
fying, albeit likely not final, description of
the ribosomal mechanism of peptide-
bond formation. The enzymatic reaction
follows the template model, viz. a precise
stereochemical alignment of the CCA-
ends of both A- and P-tRNAs by the A
and P loops, respectively, brings the reac-
tants into a proper stereochemical posi-
tion. The reaction itself involves a proton
shuttle (Figure 1B, left panel), where a pro-
ton moves from the a-amino group of the
A-tRNA to the 20-O of the P-tRNA, which
gives its own proton to the 30-O of the
P-tRNA during cleavage of the corre-
sponding ester bond. The 20-OH of
A2451 hydrogen-bonds the 20-O of the
P-tRNAduring thewhole reactionprevent-
ing transesterification and holding it in the
RNA-unfavorable 20-endo configuration,
which however favors the proton shuttle.
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Figure 1. Peptide-Bond Formation on the Ribosome
(A) Both acyl groups of the P- and A-tRNA are linked to the ribose at the 30 position.
(B) The main players for the mechanism. Left panel, pairwise movement of the electrons illustrating the
proton shuttle. Right panel, the distances between the 20-OH groups of A76 of the P-tRNA and A2451
and the a-amino group of the A-tRNA are given.
(C) The mechanism: (Upper left) The starting situation with an fMet-tRNA at the P site and a Phe-tRNA at
the A site; only the main players are shown (see [B], right panel). The ester carbonyl carbon is attacked by
the lone pair of the sp3 hybridized a-amino group (black arrow). (Upper right) The tetrahedral intermediate
is formed. Note the proton shuttle from the a-amino group of the A-tRNA to the 20-O of A76 of the P-tRNA,
whereas that from the 20-O moves to the 30-O of the P-tRNA. The black arrows indicate the pairwise elec-
tronmovement for proton shuttling. (Lower right) Configuration after the proton shuttling. (Lower left) Prod-
ucts after peptide-bond formation: a deacylated tRNA is at the P site and an fMet-Phe-tRNA at the A site.
The H-bridge from 20-OH of A2451 to the 20-O of the P-tRNA is maintained throughout the reaction. Co-
ordinates fromPDB entry 1VQN (Schmeing et al., 2005), but with an f-Met residue on the P-tRNA.Modified
from Figure 3 of Lang et al., (2008).418 Chemistry & Biology 15, May 2008 ª2008 Elsevier Ltd All rights reserved
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Targeted degradation of proteins by the
ubiquitin-proteasome pathway plays an
essential role in the regulation of protein
homeostasis and in the regulation of
essentially every function of the living
cells. The proteasome is a large,multisub-
unit, proteolytic complex that proces-
sively degrades ubiquitinylated proteins
into small peptides. Numerous inhibitors
of this degradation machine, discovered
in the past 15 years, serve as excellent
tools to determine proteasome involve-
ment in a cellular or physiological process
and to determine if a protein of interest is
degraded by the proteasomes (Kisselev
and Goldberg, 2001). Proteasome inhibi-
tors cause selective apoptosis of malig-
nant cells, and represent a new class of
antineoplastic agents (Adams, 2004).
One such inhibitor, bortezomib (VELCADE),
has been approved by the FDA for the
treatment of multiple myeloma and
mantle cell lymphoma. Three second-
generation proteasome inhibitors, carfil-
zomib (PR-171) (Demo et al., 2007),
salinosporamide A (NPI-0052) (Chauhan
et al., 2005), and CEP-18770 (Piva et al.,
2008), are in phase I and II clinical trials
(Figure 1).
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anism of proteasome inhibition and su
now report additional proteasome inhibi-
tors. If there are so many proteasome
inhibitors already available, why do these
compounds deserve special attention?
One of them inhibits the proteasome by
a mechanism not previously described
and the other suggests potential for addi-
tional therapeutic applications of these
compounds. In addition, these inhibitors
were discovered in an unusual way.
Groll et al. (2008) set out to investigate
the mechanisms of the Syringolin A (SylA,
Figures 1 and 2) virulence factor of the
plant pathogen Pseudomonas syringie.
Treatment of wheat and Arabidopsis
thaliana with this peptide derivative leads
to changes in gene expression profiles
that resemble changes occurring in yeast
and mammalian cells treated with protea-
some inhibitors (i.e., upregulation of tran-
scripts encoding proteasomal subunits
and heat shock proteins). This observa-
tion allowed Groll et al. to hypothesize
that this compound is a proteasome in-
hibitor. Indeed they found that it irrevers-
ibly inhibits all three types of proteasomal
proteolytic sites. In order to elucidate
the mode of inhibition, they solved the
structure of SylA complex with the yeast
20S proteasome. This structure revealed
a novel mode of inhibition whereby the
hydroxy group of proteasome’s catalytic
Chemistry & Biology 15, May 2008Trobro, S., and A˚qvist, J. (2005). Proc. Natl. Acad.
Sci. USA 102, 12395–12400.
Weinger, J.S., Parnell, K.M., Dorner, S., Green, R.,
and Strobel, S.A. (2004). Nat. Struct. Mol. Biol. 11,
1101–1106.
Youngman, E.M., Brunelle, J.L., Kochaniak, A.B.,
and Green, R. (2004). Cell 117, 589–599.bitors
edical School, Lebanon, NH 03756, USA
recent study in Nature (Groll et al.,
These inhibitors, discovered in an
ggest new therapeutic application
threonine performs a Michael type 1,4-
addition to the vinyl ketone moiety in the
14-membered ring of the inhibitor (Fig-
ure 2). This mechanism resembles mech-
anisms of inhibition by another class of
proteasome inhibitors, peptidyl vinyl sul-
fones (Groll and Huber, 2004). They also
found that another microbal metabolite,
Glidobactin A (GlbA), inhibited the chymo-
trypsin- and the trypsin-like activities of
the proteasome and reacted with active
site threonines in a similar fashion. Both
SylA and GlbA blocked proliferation and
induced apoptosis of malignant cells, fur-
ther confirming that they are proteasome
inhibitors.
Hines et al. (2008) investigated the
mechanism of neurotropic activity of
marine fungal metabolite fellutamide B. It
was known that treatment of cultured
neurons and fibroblasts with this com-
pound induces nerve growth factor
(NGF) secretion, but the mechanism lead-
ing to this event had not been elucidated.
They noticed similarities in the structures
of this lipopetide aldehyde and peptide
aldehyde proteasome inhibitor MG132,
and tested whether it is a proteasome in-
hibitor. Indeed they found that fellutamide
B is a very potent inhibitor of the chymo-
trypsin-like sites and that it also inhibits
the trypsin-like and caspase-like sites,
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